Multiple Myeloma - A New Era of Treatment Strategies

Indexed in: Book Citation Index, Science Edition (BKCI-S), Web of Science, Scopus, EBSCO.

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

The Multiple Myeloma Bone Marrow Microenvironment

Pp. 128-137 (10)

DOI: 10.2174/978160805297411201010128

Author(s): Aldo M. Roccaro, Angelo Vacca, Giuseppe Rossi, Irene Ghobrial


Multiple myeloma (MM) is a plasma cell malignancy that characteristically involves extensive infiltration of bone marrow (BM), with the formation of plasmacytomas, as clusters of malignant plasma cells inside or outside the BM milieu. Despite limits to our understanding of the molecular events of neoplastic transformation in MM, substantial advances have been made in understanding the biology of the disease through the study of the BM microenvironment, which appears to be fundamental for the proliferation, survival, and resistance of myeloma; providing the preclinical evidences for targeting MM cells and BMSCs as an anti-tumor strategy in this disease.


Bone marrow stromal cells (BMSCs), cell adhesion mediated drug resistance (CAM-DR), extracellular matrix (ECM), adhesion molecules, interleukin-6, insulin-like-growth-factor 1, vascular endothelial growth factor (VEGF), bone marrow niches, B-cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), stromal derived factor-1 (SDF-1), hypoxia, BM endothelial cells (BMECs), angiogenesis.